The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…

The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
In 2001, Victoria Seligman, MD, MPH, was vacationing in Vietnam. While traveling by train, she met a student from Yale University who was working on the school’s Cambodian Genocide Program, which documents the atrocities that occurred in Cambodia between 1975 and 1979 under the Khmer Rouge regime. Approximately 1.7 million people—representing 21% of the population—were slaughtered….
Kimberly Retzlaff |
SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…
Kimberly Retzlaff |
SNOWMASS VILLAGE, COLO.—The study of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is ongoing, and research results should help improve treatment for this patient population. Key trials and therapeutic options were discussed at the 2020 ACR Winter Symposium during the session, Update on the Treatment of ANCA-Associated Vasculitis, by Peter A. Merkel, MD, MPH, chief of…
Vania Lin, MD, MPH, & Leah Krull, MD |
Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…
Bryn Nelson, PhD |
Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…
Elizabeth Park, MD |
Even before I started my rheumatology fellowship, I knew it would be a demanding career, diagnosing complex diseases with only a few management options in seriously ill patients. What I didn’t appreciate as much before is how badly we are needed across the country. According to the 2018 outcomes report from the National Resident Matching…
Philip C. Robinson, MBChB, PhD, FRACP |
Editor’s note: We are sad to announce that we have learned of the passing of Dr. Philip C. Robinson. We will share more as it becomes available, but in the meantime, we wanted to repost this article he wrote for The Rheumatologist early in the pandemic. Dr. Robinson also took the photo of the full-arc rainbow below.
Social distancing and telemedicine are creating unique challenges for pediatric rheumatologists to care for their patients—many of whom are 5 years old or younger. Sangeeta Sule, MD, PhD, discusses how her clinic is adapting…
Belinda Birnbaum, MD |
As the mystery solvers, we are supposed to be comfortable with the unknown, but how does that translate when COVID-19 hits home? A rheumatologist contracts COVID-19.